Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Manages central (cranial) diabetes insipidus. Sold as Ddavp, Concentraid, Stimate, Minirin, Desmopressin Acetate and 3 more. Every FDA application for this active ingredient: 10 branded and 28 generic.
As of Nov 16, 2026, FDA lists 38 applications for Desmopressin Acetate (sold as Ddavp, Concentraid, Stimate and others), first approved Feb 21, 1978, with 2 new uses approved and 3 published complete response letters.
First approved: Feb 21, 1978
Applications: 38
New uses approved: 2
Complete response letters: 3
Medicare spending, 2025: $574K
Shortage: Current
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Ddavp
Part D
$301K
-13%
39
Ddavp
Part B
$273K
-23%
2,335
Nocdurna
Part D
$0K
-100%
0
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
DESMOPRESSIN 10 MCG/0.1 ML SPR: $10.53 per MLGeneric · +8% in a year
DESMOPRESSIN 40 MCG/10 ML VIAL: $18.44 per MLGeneric · +2% in a year
DESMOPRESSIN ACETATE 0.1 MG TB: $0.235 per unitGeneric · -17% in a year
DESMOPRESSIN ACETATE 0.2 MG TB: $0.380 per unitGeneric · 0% in a year
Minirinmelt OD, new approvalDrugs with a new additional indication and a new dosage in an additional dosage form indicated for the treatment of nocturia due to nocturnal polyuria in males. · Ferring Pharmaceuticals Co., Ltd. · Jun 18, 2019
Minirinmelt OD, new approvalA drug with a new indication and a new dosage in an additional dosage form for the treatment of central diabetes insipidus. · Ferring Pharmaceuticals Co., Ltd. · Dec 25, 2012
Minirinmelt ODDrugs with a new indication and a new dosage for the treatment of central diabetes insipidus. · Ferring Pharmaceuticals Co., Ltd. · Dec 21, 2012
Minirinmelt OD, new approvalDrugs with a new route of administration indicated for the treatment of nocturnal enuresis associated with decreased urine osmolality or urinary specific… · Ferring Pharmaceuticals Co., Ltd. · Mar 30, 2012
DDAVP Effect by TEG6 in Cardiac SurgeryIntraoperative Bleeding · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA